Immatics (IMTX) Capital Expenditures (2019 - 2026)
Immatics (IMTX) posted Capital Expenditures of -$1.1 million for Q4 2025, up 10.98% sequentially from -$1.3 million in Q3 2025, and up 36.88% YoY from -$824903.9 in Q4 2024.
Analysis
Immatics (IMTX) Capital Expenditures (2019 - 2026) Analysis & Trends
Immatics has reported Capital Expenditures for 7 years, with the latest figure at -$1.1 million in Q4 2025.
- Quarterly Capital Expenditures rose 36.88% year-over-year to -$1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$7.2 million (up 58.95% YoY) and the FY2025 annual result came in at -$7.4 million, up 57.93% from the prior year.
- Capital Expenditures improved to -$1.1 million in Q4 2025 per IMTX's latest filing, from -$1.3 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $56.3 million in Q4 2023 and troughed at -$11.6 million in Q2 2023.
- A 5-year average of $386663.4 and a median of -$1.6 million in 2025 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures soared 545.09% in 2022, then slumped 1248.09% in 2023.
- Over 5 years, Capital Expenditures stood at -$2.1 million in 2021, then jumped by 545.09% to $9.3 million in 2022, then surged by 504.3% to $56.3 million in 2023, then slumped by 103.18% to -$1.8 million in 2024, then soared by 36.88% to -$1.1 million in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$1.1 million, -$1.3 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Immatics | 1.17 Bn | 711.21 Mn | - | -1.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.01 Mn |
| Mar 31, 2026 | -893,278.93 |
| Dec 31, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.27 Mn |
| Jun 30, 2025 | -1.62 Mn |
| Mar 31, 2025 | -3.23 Mn |
| Dec 31, 2024 | -1.79 Mn |
| Sep 30, 2024 | -3.08 Mn |
| Jun 30, 2024 | -2.82 Mn |
| Mar 31, 2024 | -9.97 Mn |
| Dec 31, 2023 | -10.00 Mn |
| Sep 30, 2023 | -7.08 Mn |
| Jun 30, 2023 | -11.64 Mn |
| Mar 31, 2023 | -4.63 Mn |
| Dec 31, 2022 | -2.40 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Jun 30, 2022 | -863,248.86 |
| Mar 31, 2022 | -1.30 Mn |
| Dec 31, 2021 | -2.09 Mn |
| Sep 30, 2021 | -1.61 Mn |